Press Releases

September 16, 2021

FDA Accepts Investigational New Drug Application for Peanut Allergy Candidate Developed by COUR Pharmaceuticals

Today, COUR Pharma announced the U.S. Food and Drug Administration accepted its Investigational New Drug Application to initiate the first clinical trial for CNP-201, a nanoparticle immune-modifying drug candidate for...
Read More
October 22, 2019

Takeda Acquires License for First-In-Class Celiac Disease Therapy from COUR Pharmaceuticals Following Positive Phase 2a Proof-of-Concept Study

Late-breaking data presented from a Phase 2a trial at UEG Week 2019, Barcelona, Spain, highlights potential of investigational medicine to prevent gluten induced immune activation in patients with celiac disease...
Read More
January 10, 2018

Cour Pharmaceuticals Receives FDA Fast Track Designation for TIMP-GLIA

Cour Pharmaceuticals Receives FDA Fast Track Designation for TIMP-GLIA – A Novel Treatment for Celiac Disease under Clinical Development TIMP-GLIA is designed to enable patients to develop tolerance to gluten...
Read More
August 21, 2017

Cour Pharmaceuticals Announces an Open Investigational New Drug (IND) Application for TIMP-GLIA – A Novel Treatment for Celiac Disease

Cour Pharmaceuticals, a specialty pharma company focused on autoimmune, allergic, and inflammatory diseases, announces that its Investigational New Drug (IND) for TIMP-GLIA is now open with the US Food &...
Read More
December 8, 2015

Takeda and Cour Partner to Develop Novel Therapies for Celiac Disease

 Takeda and Cour Partner to Develop Novel Therapies for Celiac Disease and Other Gastrointestinal Diseases  Osaka, Japan, December 8, 2015, and Chicago, Ill., December 7, 2015 – Takeda Pharmaceutical Company...
Read More